treosulfan   Click here for help

GtoPdb Ligand ID: 8281

Synonyms: Trecondi®
Approved drug
treosulfan is an approved drug (UK (1992), EMA (2019))
Compound class: Synthetic organic
Comment: Treosulfan is a DNA alkylating agent.
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: treosulfan

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 143.96
Molecular weight 278.01
XLogP -3.29
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OC(C(COS(=O)(=O)C)O)COS(=O)(=O)C
Isomeric SMILES OC(C(COS(=O)(=O)C)O)COS(=O)(=O)C
InChI InChI=1S/C6H14O8S2/c1-15(9,10)13-3-5(7)6(8)4-14-16(2,11)12/h5-8H,3-4H2,1-2H3
InChI Key YCPOZVAOBBQLRI-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
The EMA granted treosulfan orphan drug status to be used as a conditioning treatment prior to haematopoietic progenitor cell transplantation. The FDA has granted orphan drug status for the treatment of ovarian cancer. Four Phase III clinical trials assessing treosulfan as a conditioning treatment are ongoing, as are Phase III studies for ovarian cancer and Ewing's sarcoma. Full EMA approval was granted in 2019.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
As a DNA alkylating (cross-linking) agent, treosulfan treatment irreversibly interferes with DNA replication, RNA transcription and causes general disruption of nucleic acid function. This action causes cell death.